| Message: | CAS 159519-65-0 Enfuvirtide/sherry@chembj.com
Product Name: Enfuvirtide
Alias: Fuzeon
CAS: 159519-65-0
MF: C204H301N51O64
MW: 4492
Purity (HPLC): 98.0%min
Grade: Pharmaceutical Grade
Appearance: White To Off-White Amorphous Solid
Single Impurity (HPLC) : 0.5%max
Amino Acid Composition : ±10% of theoretical
Peptide Content (N%) : ≥80.0%
Water Content (Karl Fischer) : ≤8.0%
TrifluoroAcetate Content(HPIC) : ≤12.0%
MS (ESI) : Consistent
Mass Balance : 95.0~105.0%
Storage: Closed, below 2 ~ 8℃ preservation
Usage : Treatment option for patients suffering from HIV/AIDS
Description
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Application
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
|
my account
